Betty J Dong

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women
    Betty J Dong
    University of California, San Francisco, 94143 0622, USA
    AIDS 26:833-41. 2012
  2. ncbi request reprint Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism
    Betty J Dong
    School of Pharmacy, University of California San Francisco, 521 Parnassus Avenue C 152, San Francisco, CA 94143 0622, USA
    Clin Ther 27:1725-51. 2005
  3. ncbi request reprint Tipranavir: a protease inhibitor for HIV salvage therapy
    Betty J Dong
    Department of Clinical Pharmacy, School of Pharmacy, University of California at San Francisco, 94143, USA
    Ann Pharmacother 40:1311-21. 2006
  4. doi request reprint Raltegravir: the first HIV integrase inhibitor
    Jennifer Cocohoba
    Department of Clinical Pharmacy, School of Pharmacy, University of California San Francisco, San Francisco, California 94143, USA
    Clin Ther 30:1747-65. 2008
  5. pmc Reporting of critical information in studies of pharmacists in HIV care
    Jennifer Cocohoba
    Department of Clinical Pharmacy, University of California San Francisco School of Pharmacy, San Francisco, CA, USA
    Int J Pharm Pract 22:375-85. 2014
  6. doi request reprint Immunologic benefits of enfuvirtide in patients enrolled in a drug assistance program
    Parya Saberi
    Department of Family and Community Medicine, University of California at San Francisco, San Francisco, CA 94143, USA
    Ann Pharmacother 42:621-6. 2008
  7. doi request reprint Health care provider satisfaction with telephone consultations provided by pharmacists and physicians at the National HIV/AIDS Clinicians' Consultation Center
    Elizabeth M Sherman
    Department of Clinical Pharmacy, University of California, San Francisco, CA, USA
    Ann Pharmacother 45:1499-505. 2011
  8. pmc The impact of HIV clinical pharmacists on HIV treatment outcomes: a systematic review
    Parya Saberi
    Department of Medicine, University of California, San Francisco, CA, USA
    Patient Prefer Adherence 6:297-322. 2012
  9. ncbi request reprint Treatment of AIDS and HIV-related conditions--2002: antiretroviral therapy
    Ronald H Goldschrnidt
    Family Practice Residency Program, San Francisco General Hospital, University of California, San Francisco 94110, USA
    J Am Board Fam Pract 15:319-31. 2002
  10. ncbi request reprint Outcomes of dual-protease inhibitor salvage therapy in human immunodeficiency virus-infected patients referred to a telephone consultation service
    Michael L Lim
    National HIV Telephone Consultation Service, San Francisco General Hospital, California, USA
    Pharmacotherapy 23:1100-4. 2003

Detail Information

Publications11

  1. pmc Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women
    Betty J Dong
    University of California, San Francisco, 94143 0622, USA
    AIDS 26:833-41. 2012
    ..To estimate nevirapine (NVP) pharmacokinetics and examine its association with rash and/or hepatotoxicity in women starting antiretroviral treatment in the AIDS Clinical Trials Group A5208/OCTANE study in Africa...
  2. ncbi request reprint Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism
    Betty J Dong
    School of Pharmacy, University of California San Francisco, 521 Parnassus Avenue C 152, San Francisco, CA 94143 0622, USA
    Clin Ther 27:1725-51. 2005
    ..Traditional medical therapy (eg, vitamin D sterols, calcium, phosphate binders) has been inadequate for the management of HPT and its vascular and skeletal complications...
  3. ncbi request reprint Tipranavir: a protease inhibitor for HIV salvage therapy
    Betty J Dong
    Department of Clinical Pharmacy, School of Pharmacy, University of California at San Francisco, 94143, USA
    Ann Pharmacother 40:1311-21. 2006
    ..To review the efficacy, safety, pharmacology, virology, pharmacokinetics, and resistance of the nonpeptidic protease inhibitor (PI) tipranavir...
  4. doi request reprint Raltegravir: the first HIV integrase inhibitor
    Jennifer Cocohoba
    Department of Clinical Pharmacy, School of Pharmacy, University of California San Francisco, San Francisco, California 94143, USA
    Clin Ther 30:1747-65. 2008
    ..Raltegravir is the first integrase inhibitor to be approved by the US Food and Drug Administration for use in antiretroviral treatment- experienced adult patients with viral resistance...
  5. pmc Reporting of critical information in studies of pharmacists in HIV care
    Jennifer Cocohoba
    Department of Clinical Pharmacy, University of California San Francisco School of Pharmacy, San Francisco, CA, USA
    Int J Pharm Pract 22:375-85. 2014
    ..To evaluate manuscripts documenting HIV pharmacist interventions and assess adequacy of reporting as defined by CONSORT and STROBE criteria...
  6. doi request reprint Immunologic benefits of enfuvirtide in patients enrolled in a drug assistance program
    Parya Saberi
    Department of Family and Community Medicine, University of California at San Francisco, San Francisco, CA 94143, USA
    Ann Pharmacother 42:621-6. 2008
    ..Randomized clinical trials have demonstrated that enfuvirtide plus an optimized background regimen can cause a significant increase in CD4+ cell counts and a reduction in HIV RNA levels...
  7. doi request reprint Health care provider satisfaction with telephone consultations provided by pharmacists and physicians at the National HIV/AIDS Clinicians' Consultation Center
    Elizabeth M Sherman
    Department of Clinical Pharmacy, University of California, San Francisco, CA, USA
    Ann Pharmacother 45:1499-505. 2011
    ..Callers to the NCCC receive consultation from either a clinical pharmacist (PharmD) or a physician (MD) with HIV expertise...
  8. pmc The impact of HIV clinical pharmacists on HIV treatment outcomes: a systematic review
    Parya Saberi
    Department of Medicine, University of California, San Francisco, CA, USA
    Patient Prefer Adherence 6:297-322. 2012
    ..In a HIV multidisciplinary care team, the HIV pharmacist is well-equipped to provide this expertise. We conducted a systematic review to assess the impact of HIV pharmacists on HIV clinical outcomes...
  9. ncbi request reprint Treatment of AIDS and HIV-related conditions--2002: antiretroviral therapy
    Ronald H Goldschrnidt
    Family Practice Residency Program, San Francisco General Hospital, University of California, San Francisco 94110, USA
    J Am Board Fam Pract 15:319-31. 2002
  10. ncbi request reprint Outcomes of dual-protease inhibitor salvage therapy in human immunodeficiency virus-infected patients referred to a telephone consultation service
    Michael L Lim
    National HIV Telephone Consultation Service, San Francisco General Hospital, California, USA
    Pharmacotherapy 23:1100-4. 2003
    ..To determine the clinical outcomes of dual-protease inhibitor salvage therapy in heavily experienced patients after their providers consulted the National HIV Telephone Consultation Service (Warmline, 800-933-3413)...
  11. ncbi request reprint Advances in human immunodeficiency virus therapeutics
    Patrick G Clay
    Kansas City University of Medicine and Biosciences, Kansas City, MO 64106, USA
    Ann Pharmacother 40:704-9. 2006
    ..To review recent advances in the management of persons infected with HIV...